The sizable Series A underscores strong investor confidence and provides Zag Bio with the resources to fast‑track its therapeutic programs, potentially reshaping the diabetes treatment landscape and attracting further market interest.
Zag Bio, a Cambridge‑based biotech startup, secured $80 million in a Series A financing round led by T1D Fund and Polaris Partners. The new capital will support the company’s product development and growth initiatives.
Comments
Want to join the conversation?
Loading comments...